Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282843 | 0.80 | ELANE (1.00) | ELANECTRB1 | |
| SCHEMBL23881485 | 0.77 | ELANE (0.70) | ELANECTRB1 | |
| SCHEMBL4119409 | 0.77 | ELANE (0.70) | ELANE | |
| SCHEMBL26672043 | 0.77 | ELANE (0.70) | ELANECTRB1 | |
| SCHEMBL19189656 | 0.77 | ELANE (0.70) | ELANECTRB1 | |
| SCHEMBL20463303 | 0.74 | ELANE (0.66) | ELANE | |
| SCHEMBL13206696 | 0.74 | ELANE (1.00) | ELANE | |
| SCHEMBL4468051 | 0.73 | ELANE (0.64) | ELANECTRB1 | |
| SCHEMBL282876 | 0.72 | ELANE (0.62) | ELANE | |
| SCHEMBL146072 | 0.68 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199532-A1 | INTERMEDIATE FOR THE SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | Celgene Corporation (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | ELANE 3328/4885CTRB1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.